{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:21Z","timestamp":1786119261520,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1097\/fpc.0b013e32832a8e81","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T18:46:46Z","timestamp":1242931606000},"page":"415-421","source":"Crossref","is-referenced-by-count":21,"title":["Antihypertensive pharmacogenetic effect of fibrinogen-beta variant \u2212455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study"],"prefix":"10.1097","volume":"19","author":[{"given":"Amy I.","family":"Lynch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Boerwinkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry R.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Eckfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Leiendecker-Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna K.","family":"Arnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210212","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","article-title":"Heart disease and stroke statistics \u2013 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"115","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"key":"R2-4-20210212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.vph.2005.09.010","article-title":"Pharmacogenetics of antihypertensive treatment","volume":"44","author":"Arnett","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"R3-4-20210212","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/nar\/15.4.1615","article-title":"Characterization of the 5\u2032-flanking region for the human fibrinogen beta gene","volume":"15","author":"Huber","year":"1987","journal-title":"Nucleic Acids Res"},{"key":"R4-4-20210212","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/00004872-199816110-00003","article-title":"Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk in Communities (ARIC) Study","volume":"16","author":"Folsom","year":"1998","journal-title":"J Hypertens"},{"key":"R5-4-20210212","first-page":"914","article-title":"The relationship between the five beta-fibrinogen gene polymorphisms and cerebral infarction","volume":"44","author":"Fu","year":"2005","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"R6-4-20210212","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/01.CIR.103.13.1746","article-title":"Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker therapy","volume":"103","author":"Gibbs","year":"2001","journal-title":"Circulation"},{"key":"R7-4-20210212","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s11745-005-1488-8","article-title":"Overview of hemostatic factors involved in atherosclerotic cardiovascular disease","volume":"40","author":"Kannel","year":"2005","journal-title":"Lipids"},{"key":"R8-4-20210212","first-page":"CR55","article-title":"Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis","volume":"12","author":"Kirmizis","year":"2006","journal-title":"Med Sci Monit"},{"key":"R9-4-20210212","first-page":"165","article-title":"Effect of beta-Fibrinogen-455 Gene Polymorphism on Plasma Fibrinogen Levels in Patients with Ischemic Stroke","volume":"9","author":"Li","year":"2001","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"R10-4-20210212","first-page":"133","article-title":"Inflammation predicts all-cause and cardiovascular mortality in haemodialysis patients","volume":"27","author":"Selim","year":"2006","journal-title":"Prilozi"},{"key":"R11-4-20210212","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1160\/TH06-12-0715","article-title":"Fibrin clot structure in patients with end-stage renal disease","volume":"98","author":"Sjoland","year":"2007","journal-title":"Thromb Haemost"},{"key":"R12-4-20210212","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1161\/CIRCULATIONAHA.106.635029","article-title":"Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study","volume":"115","author":"Tzoulaki","year":"2007","journal-title":"Circulation"},{"key":"R13-4-20210212","first-page":"155","article-title":"Plasma lipids and blood viscosity in patients with cerebrovascular disease","volume":"35","author":"Velcheva","year":"2006","journal-title":"Clin Hemorheol Microcirc"},{"key":"R14-4-20210212","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/01.STR.0000181754.38408.4c","article-title":"Associations of inflammatory and hemostatic variables with the risk of recurrent stroke","volume":"36","author":"Woodward","year":"2005","journal-title":"Stroke"},{"key":"R15-4-20210212","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1538-7836.2007.02528.x","article-title":"Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study","volume":"5","author":"Zakai","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R16-4-20210212","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198408233110804","article-title":"Fibrinogen as a risk factor for stroke and myocardial infarction","volume":"311","author":"Wilhelmsen","year":"1984","journal-title":"N Engl J Med"},{"key":"R17-4-20210212","first-page":"1799","article-title":"Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis","volume":"294","author":"Danesh","year":"2005","journal-title":"JAMA"},{"key":"R18-4-20210212","first-page":"255","article-title":"Identification of beta-FBG-455G\/A polymorphisms in 210 samples of Guangdong population and the relationship with plasma fibrinogen level","volume":"20","author":"Liu","year":"1999","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R19-4-20210212","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2005.03.008","article-title":"Beta-fibrinogen haplotypes and the risk for cardiovascular disease in a dialysis cohort","volume":"46","author":"Liu","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R20-4-20210212","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1161\/01.ATV.19.12.3063","article-title":"Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration","volume":"19","author":"Van \u2018t Hooft","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R21-4-20210212","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1161\/01.ATV.0000222011.13026.25","article-title":"Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk","volume":"26","author":"Kathiresan","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R22-4-20210212","first-page":"491","article-title":"Effect of various antihypertensive drugs on plasma fibrinogen levels in patients with essential hypertension","volume":"55","author":"Bhatia","year":"2001","journal-title":"Indian J Med Sci"},{"key":"R23-4-20210212","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2125.1995.tb04482.x","article-title":"Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients","volume":"39","author":"Fogari","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"R24-4-20210212","first-page":"41","article-title":"Lisinopril effects on cerebral blood flow and blood rheology in hypertensive patients","volume":"76","author":"Markova","year":"2004","journal-title":"Ter Arkh"},{"key":"R25-4-20210212","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/107602960501100203","article-title":"Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension","volume":"11","author":"Papadakis","year":"2005","journal-title":"Clin Appl Thromb Hemost"},{"key":"R26-4-20210212","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.tpj.6500113","article-title":"Pharmacogenetic approaches to hypertension therapy: design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study","volume":"2","author":"Arnett","year":"2002","journal-title":"Pharmacogenomics J"},{"key":"R27-4-20210212","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1751-7176.2008.00015.x","article-title":"Blood pressure control by drug group in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"10","author":"Cushman","year":"2008","journal-title":"J Clin Hypertens"},{"issue":"4","key":"R28-4-20210212","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0895-7061(96)00037-4","article-title":"Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group","volume":"9","author":"Davis","year":"1996","journal-title":"Am J Hypertens"},{"key":"R29-4-20210212","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1001\/jama.283.15.1967","article-title":"Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"R30-4-20210212","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R31-4-20210212","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.HYP.0000086521.95630.5A","article-title":"Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"42","year":"2003","journal-title":"Hypertension"},{"key":"R32-4-20210212","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1073\/pnas.82.8.2344","article-title":"Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion","volume":"82","author":"Kant","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R33-4-20210212","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1101\/gr.9.10.936","article-title":"A multilocus genotyping assay for candidate markers of cardiovascular disease risk","volume":"9","author":"Cheng","year":"1999","journal-title":"Genome Res"},{"key":"R34-4-20210212","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/archinternmed.2007.66","article-title":"Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"168","author":"Wright","year":"2008","journal-title":"Arch Intern Med"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01213011-200906000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:50:50Z","timestamp":1786038650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01213011-200906000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e32832a8e81","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}